AIC
IART icon

Argus Investors Counsel’s Integra LifeSciences IART Stock Holding History

Argus Investors Counsel’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,386
Closed -$243K – 72
2018
Q4 		$243K Buy
5,386
+839
+18% +$46K 0.13% 68
2018
Q3 		$300K Buy
+4,547
New +$283K 0.13% 65

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Argus Investors Counsel's IART Position: Q1 2019 in Review

Argus Investors Counsel sold out of Integra LifeSciences (IART) in Q1 2019, closing a stake of 5,386 shares — an estimated $243K sold.

Argus Investors Counsel first reported a position in IART in Q3 2018 and held it in 2 quarters. The position peaked at $300K in Q3 2018. 259 funds tracked by Wall St. Rank hold IART as of Q1 2019.

  • Argus Investors Counsel reported no remaining Integra LifeSciences position as of Q1 2019 after selling out during the quarter.
  • Argus Investors Counsel sold 5,386 Integra LifeSciences shares in Q1 2019, an estimated $243K.
  • Argus Investors Counsel first reported a position in Integra LifeSciences in Q3 2018 and held it in 2 quarters.
  • Argus Investors Counsel's Integra LifeSciences position peaked at $300K in Q3 2018.
  • 259 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2019.

Based on Argus Investors Counsel's 13F filing for Q1 2019, filed 16 Apr 2019.